FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/07/2022
Back to search
Official data from USPTO
BELMONITOR COV-2
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
11/07/2022
Trademark type
Combined
Nice classes
5, 10
Filing date
12/22/2020
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
05/24/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
01
Owner location
DE
Examiner
LOOK, JEFFREY
Law office
O30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "BelMonitor" in stylized letter with "BEL" in dark blue and "MONITOR" in light blue with "COV-2" in white letters inside a light blue rectangle beneath the letters "BEL".
Holders and representatives
Holders
R. B. (pessoa física)
PharmACT Holding AG
Representatives
Brian P. Gregg MCNEES WALLACE & NURICK
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Reagents for medical use; diagnostic chemical reagents for medical use; clinical medical reagents; clinical diagnostic reagents for medical purposes; enzymes for medical purposes with all of the foregoing for use in testing and diagnosing Sars-Cov-2 exposure; medical preparations and chemicals for pharmaceutical usefor use in the treatment and disagnosis of SARSCOV-2 or Covid-19; pharmaceutical preparations in strip form for the treatment of Covid-19; pharmaceutical preparations for the prevention of disorders of the endocrine system that may be affected by Covid-19; chemical preparations for testing blood for medical purposes to determine Sars-Cov-2 or Covid-19 exposure; chemical preparations for medical purposesfor the treatment of Covid-19; chemico-pharmaceutical preparations for the treatment of Covid-19; pharmaceutical preparations for the prevention of diseases of the metabolic systemin particularSars-Cov-2; in-vitro reagents for medical diagnostic purposes to determine exposure to Sars-Cov-2; chemical preparations for pharmaceutical purposesfor treatment of Covid-19; medical diagnostic test strips for testing for Covid-19 viral infection; diagnostic agents for medical use and diagnostic reagents for medical use in testing for Sars-Cov-2 exposure; medicated mouth spray for treating Covid-19 viral infections; pharmaceutical preparations for the prevention of disorders of the metabolic system related to Sars-Cov-2 exposure; pharmaceutical preparations for the treatment of Covid-19 viral infections; chemical preparations for use in DNA analysis for medical purposes related to diagnosing and treating Sars-Cov-2; biological reagents for medical diagnostic use for medical purposes related to diagnosing and treating Sars-Cov-2; diagnostic chemical reagents for medical use related to diagnosing and treating Sars-Cov-2
Class 10
Genetic testing apparatus for medical purposes for diagnosing exposure to Sars-Cov-2; chromatogram analyzers for medical use; patient monitoring sensors and alarms; chromatographic instruments for medical use; tools for medical diagnosticsmedical ultrasound apparatusspirometerselectromagnetic medical diagnostic imaging apparatusmedical instruments for examining women's reproductive organsmedical instruments for use in performing biopsies; chromatographic apparatus for medical use; physical analyzers for medical usehematology analyzers for medical diagnostic usesbody composition analyzers for medical purposesskin moisture analyzers for medical purposesanalyzers for the analysis of body fluids; medical diagnostic saliva pads; immunoadsorption columns for medical diagnostic use; chromatographic columns for medical use; apparatus for blood monitoring for medical use; spittoons for medical purposes; all of the foregoing for use in diagnosing or treating Sars-Cov-2 infections
Publications
History of USPTO decisions and trademark events.
27 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/14/2022
XXCR
GENERIC MADRID TRANSACTION CREATED
09/14/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/24/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/22/2022
PUBO
PUBLISHED FOR OPPOSITION
02/22/2022
GPNX
NOTIFICATION PROCESSED BY IB
02/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/02/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/02/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/14/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/10/2022
RFNT
REFUSAL PROCESSED BY IB
08/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/14/2021
RFRR
REFUSAL PROCESSED BY MPU
07/14/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/13/2021
CNRT
NON-FINAL ACTION WRITTEN
07/12/2021
DOCK
ASSIGNED TO EXAMINER
07/07/2021
DOCK
ASSIGNED TO EXAMINER
06/28/2021
DOCK
ASSIGNED TO EXAMINER
06/18/2021
MAFR
APPLICATION FILING RECEIPT MAILED
03/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/08/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/04/2021
Continuous trademark protection
Get notified about every new filing that threatens BELMONITOR COV-2 or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.